Table 1.
Patient-specific mutations that may contribute to AML pathogenesis
UPN | WGS# | FAB | Age at Dx | Structural Variants1 | Clones | OS (months) | Mutated in AML2, expressed in patient3 | Mutated in AML2, not expressed in patient4 | Mutated in other cancer types5, expressed in patient3 | Inherited mutation in AML gene, expressed in patient3 |
---|---|---|---|---|---|---|---|---|---|---|
933124 | AML1 | M1 | 57 | 3 | 1 | 24.6 | NPM1, FLT3, SMC3, DNMT3A, GPR183, TTN | PCDH24, SLC15A1, PTPRT, GPR123 | PDXDC1, PRKRA 6 | |
807970 | AML2 | M1 | 38 | 0 | 2 | 54.9 | NPM1, IDH1, NRAS, CEP170, C19orf62 | FREM2 | ||
123172 | AML3 | M1 | 56 | 0 | 2 | 53.9 | NPM1, FLT3, SMC1A, PTPN11, ZFHX3, UNC5B | EPHA8, EGFL8 | BMS1, RFC1 | |
831711 | AML4 | M1 | 57 | 0 | 1 | 53.4 | STAG2, TET2 | MUC5B, CACNA1E | CAMTA1, ARHGAP5 | |
849660 | AML5 | M1 | 22 | 5 | 1 | 27 | KAT2B | |||
808642 | AML6 | M1 | 61 | 5 | 2 | 15.5 | FLT3, TET2 | ZNF687, MAP1B, TRPC1 | DDR2, ATP9B, USP44 | |
509754 | AML7 | M1 | 21 | 8 | 2 | 73.9 | NPM1, IDH1 | TRPM4, WNK4 | ||
327733 | AML8 | M1 | 32 | 3 | 2 | 56.3 | NPM1, IDH1, SLC24A3, MPND | |||
224143 | AML21 | M1 | 67 | 1 | 1 | 0.8 | NPM1, FLT3, DNMT3A | MYH14, MUC5B, MUC5B, ABCA10 | ||
545259 | AML33 | M1 | 30 | 0 | 1 | 33.7 | CEBPA | GBP4 | TRIM24 | |
548327 | AML34 | M1 | 51 | 2 | 2 | 31.9 | NPM1, IDH1 | LAMA5, EPB41L5, ANKRD24 | SOS1 | |
804168 | AML40 | M1 | 53 | 1 | 1 | 30 | NPM1, FLT3, WT1, PHF6, LRRC37B | SDK2, SRCRB4D, FAM5C, LBXCOR1, OR4C15 | MED14, DAGLB | |
709968 | AML9 | M3 | 25 | 2 | 2 | 71.7 | PML-RARA 6, FLT3 | ODZ2 | PTPN11 Y197* | |
863018 | AML10 | M3 | 62 | 4 | 2 | 69.4 | PML-RARA 6, UNC5B, COL11A2, ABL1 | GDPD4 | SHQ1, DDR2, MLC1 6 | |
478908 | AML11 | M3 | 50 | 1 | 2 | 35.5 | PML-RARA 6, FLT3, RBKS | DCT | CACNA2D3 | |
344551 | AML12 | M3 | 48 | 3 | 1 | 69.3 | PML-RARA 6, WT1, NAV1, NOS1 | C1orf168 | TTLL5, PAPPA2, BICD1 | |
673778 | AML13 | M3 | 53 | 3 | 4 | 76.1 | PML-RARA 6, ETV6, SRRM2 | TOP3B | EWSR1, MLL3-BAG2 6 | |
321258 | AML14 | M3 | 31 | 1 | 3 | 64.3 | PML-RARA 6, WAC, HIVEP1, C5orf25 | CACNA1E, SI | AFF2, USP9X, RUFY1, PRPF8 | |
758168 | AML15 | M3 | 25 | 5 | 1 | 49.8 | PML-RARA 6, AKAP13, DIS3 | DNAH9, CNTN5, MUC5B | CUL3, CELSR1 | WT1 R430* 7 |
455499 | AML16 | M3 | 29 | 3 | 2 | 37.1 | PML-RARA 6 | OVGP1 | ||
202127 | AML48 | M3 | 68 | 1 | 1 | 1 | PML-RARA 6, FLT3, HERC1 | PKD1L2, FAM5C | ||
529205 | AML49 | M3 | 59 | 2 | 2 | 31.3 | PML-RARA 6, FLT3 | EPHB1, LOC100133292 | AURKB, IKZF1, PTPRG | |
501944 | AML50 | M3 | 40 | 1 | 3 | 73.6 | PML-RARA 6 | KRTAP26-1, ZNF788 | MYCBP2, MAX, VCAM1, ARID2, KIDINS220, CNOT3 | |
943309 | AML51 | M3 | 35 | 1 | 3 | 63.1 | PML-RARA 6, FLT3 | DCTN1 |
Details regarding structural variants in Supplemental Table 5.
At least 4 separate cases of AML with somatic mutations in this gene within 222 cases analyzed.
Gene expression ≥ 800 by Affymetrix U133 Plus2 array (chip mean 1,500).
Gene expression < 800 by Affymetrix U133 Plus2 array (chip mean 1,500).
At least 4 separate cases with somatic mutations in this gene in Cosmic databases.
Structural variant
Absent in ESP cohort (N = 4540).